Pennsylvania HR 430: A Resolution designating the week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Bill Text

PRINTER'S NO. 2984
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No. 430
Session of
2026
INTRODUCED BY DELLOSO, HOHENSTEIN, VENKAT, HILL-EVANS, WAXMAN,
RIVERA, McNEILL, FREEMAN, PROBST, SANCHEZ, BURGOS AND CEPEDA-
FREYTIZ, MARCH 11, 2026
REFERRED TO COMMITTEE ON HEALTH, MARCH 11, 2026
A RESOLUTION
Designating the week of May 3 through 9, 2026, as "Tardive
Dyskinesia Awareness Week" in Pennsylvania.
WHEREAS, Serious mental illnesses such as bipolar disorder,
major depressive disorder and schizophrenia often require
treatment with antipsychotic medications for effective
management, and antipsychotic medication prescribing rates
continue to rise; and
WHEREAS, While prolonged use of antipsychotic medication may
be essential for the treatment of certain conditions, it is
associated with tardive dyskinesia (TD), a condition marked by
uncontrollable, abnormal and repetitive movements of the face,
torso, limbs or extremities; and
WHEREAS, An individual is at higher risk of TD if the
individual:
(1) is 55 years of age or older, Black or a woman; or
(2) has a mood disorder, substance use disorder,
intellectual disability, central nervous system injury or
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

high cumulative antipsychotic medication exposure;
and
WHEREAS, Approximately 60% of the estimated 800,000 United
States adults living with TD remain undiagnosed; and
WHEREAS, Even mild TD symptoms can be stigmatizing and impair
physical, social and emotional well-being, underscoring the
urgency of early screening, detection and intervention; and
WHEREAS, The American Psychiatric Association recommends
routine TD screening in its clinical guidelines for
antipsychotic treatment; and
WHEREAS, Individuals treated with antipsychotic medication or
experiencing abnormal movements should consult their health care
providers to assess TD risk, receive TD screenings and determine
appropriate treatment; and
WHEREAS, Treatments approved by the United States Food and
Drug Administration for TD can provide options for symptom
management and an improved quality of life for many individuals
living with TD; and
WHEREAS, The House of Representatives encourages TD screening
education and awareness for health care providers, patients and
care partners to help ensure that patients who are prescribed
antipsychotic medication receive care and support that aligns
with clinical best practices, including regular TD screenings;
therefore be it
RESOLVED, That the House of Representatives designate the
week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness
Week" in Pennsylvania; and be it further
RESOLVED, That the House of Representatives, in recognition
and support of "Tardive Dyskinesia Awareness Week," emphasize
the importance of early detection and intervention to improve
20260HR0430PN2984 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

outcomes for individuals living with mental health conditions
and prescribed antipsychotic medication and support efforts to
raise awareness about the causes and symptoms of TD and the
importance of routine TD screening.
20260HR0430PN2984 - 3 -
1
2
3
4